1. Home
  2. LSF vs AGEN Comparison

LSF vs AGEN Comparison

Compare LSF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laird Superfood Inc.

LSF

Laird Superfood Inc.

HOLD

Current Price

$3.45

Market Cap

42.3M

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$8.54

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LSF
AGEN
Founded
2015
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.3M
274.8M
IPO Year
2020
1999

Fundamental Metrics

Financial Performance
Metric
LSF
AGEN
Price
$3.45
$8.54
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$6.00
★ $14.50
AVG Volume (30 Days)
23.7K
★ 810.9K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
75.28
★ 100.00
EPS
N/A
★ 0.96
Revenue
★ $49,889,286.00
$42,877,086.00
Revenue This Year
$90.82
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$8.85
Revenue Growth
15.23
★ 89.95
52 Week Low
$1.96
$2.71
52 Week High
$5.89
$8.85

Technical Indicators

Market Signals
Indicator
LSF
AGEN
Relative Strength Index (RSI) 41.09 63.28
Support Level $3.56 $2.97
Resistance Level $3.59 $8.64
Average True Range (ATR) 0.20 0.48
MACD -0.02 0.09
Stochastic Oscillator 15.00 90.28

Price Performance

Historical Comparison
LSF
AGEN

About LSF Laird Superfood Inc.

Laird Superfood Inc is engaged in the development and marketing of food and beverage products focused on health and wellness. The company's product portfolio includes coffee creamers, coffee, tea, hot chocolate, hydration and beverage enhancement products, and snacks, made using natural and functional ingredients.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: